A photo of Michael Yang.

Michael B. Yang, MD


  • Division Director, Pediatric Ophthalmology
  • Ira A. Abrahamson Jr., MD Chair, Division of Pediatric Ophthalmology
  • Professor, UC Department of Ophthalmology
  • Board Certified
At Cincinnati Children’s, we use a team approach. Even if a child graduates from my care and sees another physician on our team, I am still available to see them if his or her condition worsens and requires my special expertise.

About

Biography

As a pediatric eye doctor and division director in pediatric ophthalmology, I generally care for patients with more complicated eye conditions.

I try to make sure that parents understand their child's eye problem and work with them to provide the best care possible — whether their child’s condition is simple or complex. I care for children with nystagmus with abnormal head postures, pediatric cataracts, pediatric glaucoma, retinopathy of prematurity and strabismus. I have a special interest in superior oblique palsies, and I also treat adults with strabismus.

At Cincinnati Children’s, we use a team approach. Even if a child graduates from my care and sees another physician on our team, I am still available to see them if his or her condition worsens and requires my special expertise.

I developed a fascination with eye movements when studying biomedical engineering at Johns Hopkins. Always attracted to the brain, in medical school I cultivated an interest in ophthalmology. My pediatric ophthalmology professors at the University of Southern California were compassionate, kind and very knowledgeable role models. They influenced me to go into advanced pediatric ophthalmology training. My mentors at the University of Michigan, Steve Archer, MD, and Monte Del Monte, MD, provided personalized training in the final stage of my formal education.

My research focuses on understanding and improving care for retinopathy of prematurity (ROP). I study:

  • Better treatments with low dose anti-VEGF (Anti–vascular endothelial growth factor) therapy agents that stop the growth of extra blood vessels and improve vision.
  • Better prediction of which premature infants will develop ROP. This could lead to improved screening guidelines, letting us screen fewer infants at low risk.

I’m humbled to have received honor awards from the American Academy of Ophthalmology and the American Association for Pediatric Ophthalmology and Strabismus (AAPOS). I’ve also served on the editorial board for the Journal of AAPOS.

When I’m not at work, I enjoy playing the piano and attending my kids’ activities — whether dance or golf. I also like watching basketball and football.

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Selected

Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. Wallace, DK; Kraker, RT; Freedman, SF; Crouch, ER; Bhatt, AR; Hartnett, ME; Yang, MB; Rogers, DL; Hutchinson, AK; VanderVeen, DK; et al. JAMA Ophthalmology. 2020; 138:698-701.

Selected

Validation of the Postnatal Growth and Retinopathy of Prematurity Screening Criteria. Yang, MB; Yu, Y; Ying, G; Duros, TB; Nguyen, A; Maguire, MG; Brightwell-Arnold, M; Shaffer, J; Blanco, M; Brown, T; et al. JAMA Ophthalmology. 2020; 138:31-37.

Selected

Treatment of non-type 1 retinopathy of prematurity in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) study. Liu, T; Tomlinson, LA; Ying, GS; Yang, MB; Binenbaum, G. Journal of AAPOS. 2019; 23:332.e1-332.e6.

Selected

Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial. Phelps, DL; Watterberg, KL; Nolen, TL; Cole, CA; Cotten, CM; Oh, W; Poindexter, BB; Zaterka-Baxter, KM; Das, A; Lacy, CB; et al. JAMA - Journal of the American Medical Association. 2018; 320:1649-1658.

Selected

Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients. Rice, ML; Wong, B; Horn, PS; Yang, MB. Journal of AAPOS. 2018; 22:192-196.

Selected

Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. Wallace, DK; Kraker, RT; Freedman, SF; Crouch, ER; Hutchinson, AK; Bhatt, AR; Rogers, DL; Yang, MB; Haider, KM; VanderVeen, DK; et al. JAMA Ophthalmology. 2017; 135:654-656.

Selected

Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology. VanderVeen, DK; Melia, M; Yang, MB; Hutchinson, AK; Wilson, LB; Lambert, SR. Ophthalmology. 2017; 124:619-633.

Selected

Length of day during early gestation as a predictor of risk for severe retinopathy of prematurity. Yang, MB; Rao, S; Copenhagen, DR; Lang, RA. Ophthalmology. 2013; 120:2706-2713.

Selected

A direct and melanopsin-dependent fetal light response regulates mouse eye development. Rao, S; Chun, C; Fan, J; Kofron, JM; Yang, MB; Hegde, RS; Ferrara, N; Copenhagen, DR; Lang, RA. Nature. 2013; 494:243-246.

Selected

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey